Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: DARPA who wrote (1625)	9/11/1998 12:53:00 PM
From: Brad	Respond to of 4650

DARPA, ADOT & Biomoda have several options along the way. They are preparing for the possibilities of each. From all I have learned, I see the most likely option as Biomoda's diagnostic technology being bought out by ScheringAG/Berlex or another major pharmaceutical player. It is logical that this could happen as soon as the major player is adequately convinced of the efficacy of the TCPP process. Biomoda has said on numerous occasions that ScheringAG/Berlex just wants to see the LungCheck results. The longer a prospective buyer waits for results, the higher the price will go because the more proof they provide, the easier it is to sell. And Biomoda is perfectly content to wait because they know how effective the TCPP process is. My guess is a buyout is possible as early as 30-60 days. ScheringAG/Berlex has an annual budget for outside developing technology of $750 million per year. To buyout Biomoda for 10-20% of that yearly budget would be small change to them. You can do the math on what that would do for ADOT. I'm sure Les Robins has already done the math. So have I.